| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H17ClN2 |
| Molecular Weight | 236.74 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCC1=C(C)NC2=C1C=C(Cl)C=C2
InChI
InChIKey=KSYMELKKLOFABL-UHFFFAOYSA-N
InChI=1S/C13H17ClN2/c1-9-11(6-7-16(2)3)12-8-10(14)4-5-13(12)15-9/h4-5,8,15H,6-7H2,1-3H3
| Molecular Formula | C13H17ClN2 |
| Molecular Weight | 236.74 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
ST1936 is a potent serotonin 6 (5-HT6) receptor agonist with activity in animal pharmacological models for central nervous system disorders: effect of ST 1936 was investigated on depression-like experimental models. In addition, ST 1936 displays moderate affinity for human α2 adrenergic receptors, shown to increase Ca2+ concentration and phosphorylation of Fyn kinase, and regulate the activation of ERK1/2 in cloned cells.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
in rats: It was investigated the effect of ST1936 (5-10-20 mg/kg/ip) on dialysate DA, NA and 5-HT in the medial prefrontal cortex (PFCX) and in the shell and core of the nucleus accumbens (NAc). Systemic administration of ST1936 dose-dependently increased dialysate DA and NA in the NAc shell and PFCX and to a lesser extent in the NAc core.
Route of Administration:
Intraperitoneal
